Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leptazumab
- Development stage
- Unknown
- Lead developer
- IngenOx
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Leptazumab (also known as CXD102) is a monoclonal antibody that functions as an immune checkpoint inhibitor by targeting the programmed cell death protein 1 (PD-1) receptor. Developed by Celleron Therapeutics (now IngenOx Therapeutics), it is designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby revitalizing T-cell mediated anti-tumor immune responses. Leptazumab is primarily being investigated for the treatment of advanced hepatocellular carcinoma (HCC). It is frequently studied in combination with zabadinostat (CXD101), an HDAC inhibitor, in clinical trials such as the HACCA study, where the epigenetic modulation of zabadinostat is intended to enhance the efficacy of the PD-1 blockade.
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on leptazumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leptazumab.